SUNPHARMA · Biotechnology & Drugs · INE044A01036
Analyst mean 1.94 · 33 analysts · 17% bullishWhat the numbers mean when read together — computed from the filings, not a score.
Operating cash flow is 108% of trailing profit — the earnings are converting to cash, not just accruals.
Last operating cash flow ₹12,419 cr against trailing net profit ₹11,509 cr. A ratio at or above ~0.9 means reported profit is showing up as real cash.
Both revenue and profit grew over the last year (11.2% and 5%) — growth is translating to the bottom line.
Trailing revenue ₹58,462 cr, trailing profit ₹11,509 cr. Profit growing at least as fast as revenue indicates operating leverage or pricing power.
Free cash flow is positive and consistent — the business funds itself after capex.
Latest free cash flow ₹8,906 cr. Negative in only 1 of 12 years. A self-funding business needs less external capital and dilutes less.
Borrowings rose 41% over two years while the company also carries ₹24,723 cr in investments. Why borrow at interest while parking money elsewhere is a fair question.
Borrowings moved to ₹4,627 cr from ₹3,274 cr. Simultaneous large investments can be legitimate treasury management, or a sign that reported cash is not freely available.
Markers show corporate actions (splits, bonus, dividends). Prices are split-adjusted so the series is continuous.
| Metric | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 |
| Expenses | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 |
| Other Income | 533 | 354 | 149 | 251 | -354 | 470 | 89 | 458 |
| Depreciation | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 |
| Profit before tax | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 |
| Net Profit | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 |
| EPS | 11.82 | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 |
| Item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 240 | 240 | 240 | 240 | 240 | 240 |
| Reserves | 46,223 | 47,771 | 55,755 | 63,427 | 71,978 | 83,330 |
| Borrowings | 3,869 | 1,290 | 6,886 | 3,274 | 2,362 | 4,627 |
| Fixed Assets | 21,553 | 22,665 | 24,065 | 23,248 | 22,586 | 32,822 |
| CWIP | 1,567 | 1,287 | 4,973 | 5,354 | 6,644 | 3,052 |
| Investments | 9,612 | 12,849 | 14,824 | 15,026 | 18,354 | 24,723 |
| Total Assets | 67,622 | 69,776 | 80,712 | 85,328 | 91,908 | 108,407 |